Skip to main content
    G

    Ginkgo Bioworks Holdings (DNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $9.61
    -0.62 (-6.06%)

    Market Cap: $622.97M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Ginkgo Bioworks Holdings (DNA) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Ginkgo Bioworks Holdings reported EPS of -$0.64, below the -$0.58 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    37%(7/19)
    Avg Surprise
    -22.53%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$1.27
    RangeN/A
    2 analysts
    Revenue Consensus
    $23.03M
    Range$22.25M - $24.05M
    4 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$1.05
    Range-$1.05 - -$1.05
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current-$1.05
    Revenue Consensus
    $22.10M
    Range$19.70M - $24.10M
    3 analysts

    Next Report

    DNA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    DNA Earnings Call

    The latest DNA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 19 quarters below that had an estimate, DNA beat 7, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $27.71M, down 5.7% from $29.38M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.64-$0.58-$0.58 - -$0.50-10.34%MissN/A20 up, 0 downNov 5, 2026$27.71M
    Jun 30, 2026-$0.86-$0.70-$0.70 - -$0.70-22.86%MissN/A10 up, 0 downAug 5, 2026$20.16M
    Mar 31, 2026-$1.39-$1.34-$1.34 - -$1.34-3.73%MissN/A10 up, 1 downMay 7, 2026$19.47M
    Dec 31, 2025-$1.42-$1.80N/A+21.11%BeatN/A10 up, 0 downFeb 26, 2026$33.40M
    Sep 30, 2025-$1.45-$1.24-$1.27 - -$1.21-16.94%MissN/A32 up, 1 downNov 6, 2025$29.38M
    Jun 30, 2025-$1.10-$1.44N/A+23.61%BeatN/AN/A0 up, 0 downAug 7, 2025$39.13M
    Mar 31, 2025-$1.68-$1.77N/A+5.08%BeatN/AN/A0 up, 0 downMay 6, 2025$38.23M
    Dec 31, 2024-$2.00-$0.06N/AN/AN/AN/A10 up, 1 downFeb 25, 2025$43.85M
    Sep 30, 2024-$1.08-$3.32N/A+67.47%BeatN/A31 up, 0 downNov 12, 2024$89.05M
    Jun 30, 2024-$4.40-$3.12-$3.20 - -$2.80-41.03%MissN/A50 up, 0 downAug 8, 2024$56.21M
    Mar 31, 2024-$0.08-$0.08-$0.10 - -$0.080.00%In lineN/A60 up, 0 downMay 9, 2024$37.94M
    Dec 31, 2023-$2.94-$2.80-$5.60 - -$2.40-5.00%MissN/A60 up, 0 downFeb 29, 2024$34.76M
    Sep 30, 2023-$3.65-$3.20-$4.00 - -$2.40-14.06%MissN/A70 up, 0 downNov 8, 2023$55.43M
    Jun 30, 2023-$3.06-$3.50-$4.40 - -$2.40+12.57%BeatN/A70 up, 0 downAug 9, 2023$80.57M
    Mar 31, 2023-$3.89-$3.90-$4.80 - -$2.40+0.26%BeatN/A60 up, 0 downMay 10, 2023$80.70M
    Dec 31, 2022-$0.09-$0.21-$0.42 - -$0.05+57.14%BeatN/A70 up, 0 downMar 1, 2023$98.28M
    Sep 30, 2022-$16.51-$9.68-$16.40 - -$2.40-70.56%MissN/A50 up, 0 downNov 14, 2022$66.40M
    Jun 30, 2022-$16.44-$5.44N/A-202.21%MissN/A30 up, 0 downAug 15, 2022$144.62M
    Mar 31, 2022-$14.80-$7.40N/A-100.00%Miss-49433.3%30 up, 0 downMay 16, 2022$168.41M
    Dec 31, 2021-$0.99-$0.04-$0.06 - -$0.01N/AN/AN/A60 up, 0 downMar 28, 2022$148.49M
    Sep 30, 2021-$3.20-$1.40-$1.60 - -$1.20-128.57%MissN/A2N/ANov 15, 2021$77.61M
    Jun 30, 2021-$0.50N/AN/AN/AN/AN/AN/AN/ASep 20, 2021$43.64M
    Mar 31, 2021$0.03N/AN/AN/AN/AN/AN/AN/AMay 24, 2021$44.10M
    Last 23 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.65, after -$7.56 the year before. It was -$4.66 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.65N/A
    Dec 31, 2024-$7.56N/A
    Dec 31, 2023-$13.54N/A
    Dec 31, 2022-$47.84N/A
    Dec 31, 2021-$4.66N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,300 words across 3 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,2643
    2026Q2Jun 30, 20267,1153
    2026Q1Mar 31, 20264,1784
    2025Q4Dec 31, 20253,7893
    2025Q3Sep 30, 20254,0803
    2025Q2Jun 30, 20256,5013
    2025Q1Mar 31, 20252,2425
    2024Q4Dec 31, 20245,2476

    2026Q3 Earnings Call

    Opening remarks

    Daniel Marshall Manager of Communications and Ownership I'm joined by Jason Kelly, our Co-Founder and CEO, and Steve Coen, our CFO. Thanks, as always, for joining us. We're looking forward to updating you on our progress. As a reminder, during the presentation today, we will be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K. Today, in addition to updating you on the quarter's results, we're going to show how Ginkgo is now two businesses built on one autonomous lab platform at a moment when the U.S. government is starting to treat autonomous labs as national infrastructure. We'll share how our autonomous labs business is growing, including our first autonomous lab sale to a pharma company, Novo, alongside new government wins with ARPA-H and the NSF. We'll also share how our cloud lab business is growing with new pharma logos, including 22 customers this quarter, and with AI data generation for frontier labs. As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors, and the public. You can submit those questions to us in advance via X, #GinkgoResults, or email investors@ginkgobioworks.com. All right. Over to you, Jason.

    Jason Kelly Co-Founder and CEO Thanks, Daniel. As I always say, our mission here at Ginkgo is to make biology easier to engineer. Over the last few years, we've been going through a transformation with this focus on autonomous labs, and that was really our goal in 2026. I would say I think that succeeded very well, and this quarter is really good evidence of that. We've been focusing our efforts on moving more and more of our internal lab work onto autonomous labs. That continues, along with improving the product. But there was a real breakthrough in the last quarter in terms of external customers adopting our systems. And so we'll be happy to talk about some of the new customers we have for autonomous labs, both in universities and the biopharma sector, and we've been expanding the services that we're offering on top of our big system in Boston here in Nebula. So, really happy about this. I think we made the right choice in betting on this technology. So you're going to hear more from me on that in the strategic section. Also, our financials have been going in the right direction. We made a big push to cut back on spending while still making major investments in research and development around autonomous labs, AI, and robotics in the laboratory, and that has also paid off.

    Frequently Asked Questions About DNA

    Did DNA beat earnings estimates last quarter?

    No. Ginkgo Bioworks Holdings reported EPS of -$0.64 for the quarter ended Sep 30, 2026, below the -$0.58 estimate by 10.34%.

    What EPS do analysts expect from DNA next quarter?

    The consensus EPS estimate for Ginkgo Bioworks Holdings for the quarter ending Dec 31, 2026 is -$1.27 from 2 analysts.

    How often does DNA beat earnings estimates?

    Ginkgo Bioworks Holdings beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +7.93%.